Melanoma Antibody (DA180)
Melanoma Antibody (DA180)
Recombinant monoclonal rabbit antibody
Description
Melanoma reacts against an antigen present in melanocytic tumors and is absolute specific for melanoma. The antibody stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin.1-7
References
1. Gown AM, Vogel AM, et al. (1986) Monoclonal Antibodies Specific for Melanocytic Tumors. Distinguish Subpopulations of Melanocytes. Am J Pathol. 123(2): 195-203.
2. Baisden BL, Askin FB et al. (2000) HMB-45 immunohistochemical staining of sentinel lymph nodes: a specific method for enhancing detection of micrometastases in patients with melanoma. Am J Surg Pathol. 24(8):1140-6.
3. Smith NE, Illei PB, Allaf M et al. (2014): t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases. Am J Surg Pathol. 38(5):604-14.
4. Clarkson KS, Sturdgess IC and Molyneux AJ (2001): The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol. 54(3):196-200.
5. Yaziji H and Gown AM (2003): Immunohistochemical markers of melanocytic tumors. Int J Surg Pathol. 11(1):11-5.
6. Sheffield MV, Yee H, Dorvault CC et al. (2002): Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations. Am J Clin Pathol. 118(6):930-6.
7. Wick MR, Swanson PE and Rocamora A (1988): Recognition of malignant melanoma by monoclonal antibody HMB-45. An immunohistochemical study of 200 paraffin-embedded cutaneous tumors. J Cutan Pathol. 15(4):201-7.
2. Baisden BL, Askin FB et al. (2000) HMB-45 immunohistochemical staining of sentinel lymph nodes: a specific method for enhancing detection of micrometastases in patients with melanoma. Am J Surg Pathol. 24(8):1140-6.
3. Smith NE, Illei PB, Allaf M et al. (2014): t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases. Am J Surg Pathol. 38(5):604-14.
4. Clarkson KS, Sturdgess IC and Molyneux AJ (2001): The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol. 54(3):196-200.
5. Yaziji H and Gown AM (2003): Immunohistochemical markers of melanocytic tumors. Int J Surg Pathol. 11(1):11-5.
6. Sheffield MV, Yee H, Dorvault CC et al. (2002): Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations. Am J Clin Pathol. 118(6):930-6.
7. Wick MR, Swanson PE and Rocamora A (1988): Recognition of malignant melanoma by monoclonal antibody HMB-45. An immunohistochemical study of 200 paraffin-embedded cutaneous tumors. J Cutan Pathol. 15(4):201-7.
Specifications
Application:
IHC (FFPE)
Host:
Rabbit
Subclass:
IgG
Immunogen:
Synthetic peptide of human Melanoma
Cellular location:
Cytoplasm
Control:
Melanoma
Order information
| DMRD0223 | Concentrate | IVD(R) |
| DMRD0223 | 10 ml Ready to use | IVD(R) |
| DMRD0223 | 6 ml Ready to use | IVD(R) |
| DMRD0223 | 3 ml Ready to use | IVD(R) |
